ECSP10010231A - Derivados de 7-azaindol como inhibidores selectivos de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1. - Google Patents

Derivados de 7-azaindol como inhibidores selectivos de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1.

Info

Publication number
ECSP10010231A
ECSP10010231A EC2010010231A ECSP10010231A ECSP10010231A EC SP10010231 A ECSP10010231 A EC SP10010231A EC 2010010231 A EC2010010231 A EC 2010010231A EC SP10010231 A ECSP10010231 A EC SP10010231A EC SP10010231 A ECSP10010231 A EC SP10010231A
Authority
EC
Ecuador
Prior art keywords
beta
selective inhibitors
derivatives
azaindol
dehydrogenase type
Prior art date
Application number
EC2010010231A
Other languages
English (en)
Inventor
Denis Carniato
Melanie Schultz
Didier Roche
Sophie Hallakou-Bozec
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ECSP10010231A publication Critical patent/ECSP10010231A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

La presente invención se refiere a derivados 7-azaindol de fórmula I, como inhibidores selectivos de la enzima 11-beta-hidroxiesteroide deshidrogenasa de tipo 1 (11?-HSD-1) y el uso de dichos compuestos para el tratamiento y prevención del síndrome metabólico, diabetes, resistencia a la insulina, obesidad, trastornos lipídicos, glaucoma, osteoporosis, trastornos cognitivos, ansiedad, depresión, trastornos inmunitarios, hipertensión y otras enfermedades y afecciones.
EC2010010231A 2007-11-05 2010-06-03 Derivados de 7-azaindol como inhibidores selectivos de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1. ECSP10010231A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07291325 2007-11-05

Publications (1)

Publication Number Publication Date
ECSP10010231A true ECSP10010231A (es) 2010-07-30

Family

ID=40445347

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010231A ECSP10010231A (es) 2007-11-05 2010-06-03 Derivados de 7-azaindol como inhibidores selectivos de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1.

Country Status (23)

Country Link
US (1) US8470849B2 (es)
EP (1) EP2247589B1 (es)
JP (1) JP5529743B2 (es)
KR (1) KR101624596B1 (es)
CN (1) CN101848910B (es)
AU (1) AU2008324525B2 (es)
BR (1) BRPI0819219B1 (es)
CA (1) CA2704803C (es)
CO (1) CO6270308A2 (es)
CY (1) CY1113645T1 (es)
DK (1) DK2247589T3 (es)
EA (1) EA019707B1 (es)
EC (1) ECSP10010231A (es)
ES (1) ES2400105T3 (es)
HR (1) HRP20130097T1 (es)
IL (1) IL205508A (es)
MX (1) MX2010004815A (es)
PL (1) PL2247589T3 (es)
PT (1) PT2247589E (es)
SI (1) SI2247589T1 (es)
UA (1) UA102379C2 (es)
WO (1) WO2009059666A1 (es)
ZA (1) ZA201004023B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CN102947295B (zh) * 2010-04-29 2016-01-20 爱丁堡大学 作为11β-HSD1抑制剂的3,3-二取代的-(8-氮杂双环[3.2.1]辛烷-8-基)-[5-(1H-吡唑-4基)-噻吩-3-基]-甲酮
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives
CN106279154A (zh) * 2016-08-02 2017-01-04 叶芳 一种7‑氮杂吲哚‑3‑甲醛的制备方法
EP4172158A4 (en) * 2020-06-30 2024-01-10 Univ California COMPOSITIONS AND METHODS FOR MODULATING HAIR GROWTH
CN112390815B (zh) * 2020-11-03 2022-07-26 浙江医药股份有限公司新昌制药厂 一种Lewis酸脱N-苄基制备d-生物素的制备方法
CN112409353A (zh) * 2020-11-27 2021-02-26 苏州艾缇克药物化学有限公司 一种7-氮杂吲哚衍生物的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4307073B2 (ja) * 2000-12-22 2009-08-05 ワイス ５−ヒドロキシトリプトアミン−６リガンドとしてのヘテロサイクルインダゾールおよびアザインダゾール化合物
DE10252666A1 (de) * 2002-11-11 2004-08-05 Grünenthal GmbH N-Piperidyl-cyclohexan-Derivate
DE10337184A1 (de) * 2003-08-13 2005-03-10 Gruenenthal Gmbh Substituierte 3-Pyrrolidin-Indol-Derivate
DK1680124T3 (en) * 2003-10-14 2017-08-21 Pfizer Prod Inc Bicyclic [3.1.0] derivatives as glycine transporter inhibitors
WO2007050381A2 (en) * 2005-10-24 2007-05-03 Janssen Pharmaceutica, N.V. 3-piperidin-4-yl-indole orl-1 receptor modulators
US7638062B2 (en) 2006-07-10 2009-12-29 Cameron International Corporation Ultra compact cyclonic flotation system

Also Published As

Publication number Publication date
US20100267761A1 (en) 2010-10-21
HRP20130097T1 (hr) 2013-02-28
ZA201004023B (en) 2011-03-30
WO2009059666A1 (en) 2009-05-14
IL205508A0 (en) 2010-12-30
EP2247589B1 (en) 2012-11-21
AU2008324525B2 (en) 2014-09-18
CO6270308A2 (es) 2011-04-20
KR20100094500A (ko) 2010-08-26
EA201000751A1 (ru) 2010-12-30
AU2008324525A1 (en) 2009-05-14
DK2247589T3 (da) 2013-01-21
PT2247589E (pt) 2013-02-20
BRPI0819219A2 (pt) 2020-08-04
KR101624596B1 (ko) 2016-05-26
MX2010004815A (es) 2010-05-27
EP2247589A1 (en) 2010-11-10
SI2247589T1 (sl) 2013-03-29
CN101848910A (zh) 2010-09-29
EA019707B1 (ru) 2014-05-30
CN101848910B (zh) 2013-12-04
PL2247589T3 (pl) 2013-03-29
IL205508A (en) 2013-06-27
JP2011502135A (ja) 2011-01-20
ES2400105T3 (es) 2013-04-05
US8470849B2 (en) 2013-06-25
CA2704803A1 (en) 2009-05-14
BRPI0819219B1 (pt) 2021-09-21
UA102379C2 (ru) 2013-07-10
CY1113645T1 (el) 2016-06-22
CA2704803C (en) 2017-04-11
JP5529743B2 (ja) 2014-06-25

Similar Documents

Publication Publication Date Title
ECSP10010231A (es) Derivados de 7-azaindol como inhibidores selectivos de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1.
ECSP10010656A (es) Nuevos derivados de nip tiazol como inhibidores de la 11-beta-hidroxiesteroide deshidrogenasa-1
BRPI0619839B8 (pt) derivados de 2-adamantiluréia, seu método de preparação e seus usos, composição farmacêutica, e kit
IL184328A0 (en) Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase
CR10401A (es) Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
ECSP13012900A (es) Novedosos derivados de azabencimidazol cíclico útiles como agentes antidiabéticos
MX347145B (es) Derivados de adamantilo-acetamida como inhibidores de la enzima tipo i de 11-beta-hidroxiesteroide deshidrogenasa.
CL2008000198A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis.
NI201000013A (es) Sulfonamidas como moduladores del trpm8
UY28774A1 (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes.
CL2007003440A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9 desaturasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, resistencia a la insulina, trastornos de lipidos, obesida
GEP20135793B (en) Heteroaryls amide derivatives and their use as glucokinase activators
CR11183A (es) Espirociclos como inhibidores de la 11-beta hidroxiesteroide deshidrogenasa de tipo 1
ATE556050T1 (de) Inhibitoren des 11-beta-hydroxysteroid- dehydrogenase-1-enzyms
CR20110255A (es) Nuevos compuestos 578
ECSP088839A (es) Derivados de lactamas de ciclohexilpirazol como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
MX2007008239A (es) Inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo 1.
CY1110928T1 (el) Παραγωγα διαζεπανης-ακεταμιδης ως εκλεκτικοι 11-usd1 αναστολεις
MX2010005861A (es) Agonistas novedosos de los receptores de glucocorticoides.
UY32778A (es) Terapia de combinación para el tratamiento de la diabetes
UY31228A1 (es) Ariloxazoles sustituidos y su uso
UY32312A (es) 4-azetidinil-1-heteroaril-ciclohexanol antagonistas del ccr2
CR20110318A (es) Compuestos, composición farmacéutica y métodos para utilizarse en el tratamiento de trastornos metabólicos
MX2011011082A (es) Derivados de amida y amidina novedosos y usos de los mismos.
CO6321281A2 (es) Derivados de tetrazol como moduladores de receptores de glutamato metabotropicos (mglurs)